×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:BLFS

BioLife Solutions Stock Forecast, Price & News

$14.64
+0.83 (+6.01%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.67
$14.76
50-Day Range
$10.54
$15.72
52-Week Range
$10.40
$60.67
Volume
355,430 shs
Average Volume
514,281 shs
Market Capitalization
$620.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.17

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
188.0% Upside
$42.17 Price Target
Short Interest
Bearish
12.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of BioLife Solutions in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.33 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.39) to $0.24 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.88 out of 5 stars

Medical Sector

645th out of 1,428 stocks

Electromedical Equipment Industry

10th out of 30 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BioLife Solutions logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Stock News Headlines

BioLife Solutions Tops Q1 EPS by 8c
BioLife Solutions Q4 2021 Earnings Preview
Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt?
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/03/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$42.17
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+188.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-7.64 million
Pretax Margin
-24.76%

Debt

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$11.80 per share

Miscellaneous

Free Float
39,908,000
Market Cap
$620.88 million
Optionable
Not Optionable
Beta
1.91














BioLife Solutions Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2022?

6 brokers have issued 12 month target prices for BioLife Solutions' shares. Their BLFS stock forecasts range from $30.00 to $65.00. On average, they anticipate BioLife Solutions' stock price to reach $42.17 in the next year. This suggests a possible upside of 188.0% from the stock's current price.
View analysts' price targets for BioLife Solutions
or view top-rated stocks among Wall Street analysts.

How has BioLife Solutions' stock price performed in 2022?

BioLife Solutions' stock was trading at $37.27 at the beginning of the year. Since then, BLFS shares have decreased by 60.7% and is now trading at $14.64.
View the best growth stocks for 2022 here
.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for BioLife Solutions
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings results on Monday, May, 9th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. The medical equipment provider earned $36.22 million during the quarter, compared to the consensus estimate of $37.87 million. BioLife Solutions had a negative net margin of 10.35% and a negative trailing twelve-month return on equity of 6.24%. During the same quarter in the previous year, the company earned $0.01 EPS.
View BioLife Solutions' earnings history
.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $159.50 million-$171.00 million, compared to the consensus revenue estimate of $165.38 million.

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:

What is Mike Rice's approval rating as BioLife Solutions' CEO?

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $14.64.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $620.88 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7.64 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for BioLife Solutions is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.